A Safety Study of SGN-CD47M in Patients With Solid Tumors

Colorectal Cancer Clinical Trial

Official title:

A Phase 1 Study of SGN-CD47M in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03957096
• Other study ID #: SGN47M-001
• Status: Terminated
• Phase: Phase 1
• Start date: July 17, 2019
• Est. completion date: September 14, 2020

Study information

• Verified date: September 2020
• Source: Seattle Genetics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial will study SGN-CD47M to find out whether it is an effective treatment for different types of solid tumors and what side effects (unwanted effects) may occur. The study will have two parts. Part A of the study will find out how much SGN-CD47M should be given for treatment and how often. Part B of the study will use the dose found in Part A and look at how safe and effective the treatment is.

Description:

This is a dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of SGN-CD47M in adults with advanced solid tumors. The study will be conducted in 2 parts:

Part A - Dose escalation: Up to approximately 25 patients will be treated to evaluate the safety, tolerability, and PK of SGN-CD47M, and to identify the maximum tolerated dose (MTD) and/or optimal dose.

Part B - Dose expansion: Up to approximately 180 patients will be treated in expansion cohorts at the MTD or optimal dose to further characterize the safety, PK, and antitumor activity of SGN-CD47M.

In eligible patients, standard therapies must have failed, been intolerable, or been considered medically inappropriate by the investigator. If the MTD is not reached in Part A, safety, PK, pharmacodynamic, and biomarker analyses, as well as preliminary antitumor activity, will be used to determine the optimal dose. Patients in Part A may continue on treatment until confirmed progressive disease (PD) or unacceptable toxicity, whichever occurs first. The dose(s) to be examined in Part B will be at or below the MTD and/or the optimal dose determined in Part A.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 16
• Est. completion date: September 14, 2020
• Est. primary completion date: September 14, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the following indications:

1. Soft tissue sarcoma

2. Colorectal carcinoma

3. Non-small cell lung carcinoma

4. Head and neck squamous cell carcinoma

5. Breast carcinoma

6. Ovarian carcinoma

7. Exocrine pancreatic adenocarcinoma

8. Gastric carcinoma

9. Melanoma

• Relapsed, refractory, or progressive disease with no appropriate standard therapy available at the time of enrollment

• ECOG performance status of 0 or 1

• Measureable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at baseline

• Patients of childbearing potential may not be pregnant, must agree not to become pregnant until at 30 days after last dose of study drug, and must use 2 effective means of birth control.

• Patients who can father children must use 2 effective means of birth control and must agree not to donate sperm until at least 60 days after last dose of study drug.

Exclusion Criteria:

• History of another malignancy within 3 years prior to first dose of study drug (exceptions for malignancies with negligible risk of metastasis)

• Previous exposure to CD47 or SIRPa targeted therapy

• Chemotherapy, systemic radiotherapy, biologics, other anti-neoplastic or investigational agents, and/or other antitumor treatment with immunotherapy that is not completed 4 weeks prior to first dose of SGN-CD47M. Focal radiotherapy that is not completed 2 weeks prior to the first dose of SGN-CD47M

• Known active central nervous system metastases

• Positive for hepatitis B, active hepatitis C infections, positive for human immunodeficiency virus (HIV), or known active or latent tuberculosis

• History of sickle cell anemia, auto-immune hemolytic anemia, or idiopathic thrombocytopenic purpura

• Carcinomatous meningitis

• Red blood cell transfusion within 4 weeks prior to enrollment or platelet transfusion within 2 weeks prior to enrollment

• Any active Grade 3 or higher viral, bacterial, or fungal infection within 2 weeks prior to first dose

• History of a cerebral vascular event, unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association Class III-IV within 6 months prior to first dose

• Condition requiring systemic treatment with corticosteroids or other immunosuppressive medications within 2 week prior to first dose

• Active autoimmune disease, autoimmune-related toxicity from prior immuno-oncology-based therapy

• Estimated life expectancy of less than 12 weeks

Related Conditions & MeSH terms

• Breast Carcinoma
• Breast Neoplasms
• Carcinoma
• Carcinoma, Non-Small-Cell Lung
• Colorectal Cancer
• Exocrine Pancreatic Carcinoma
• Gastric Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Non-small Cell Lung Carcinoma
• Ovarian Carcinoma
• Pancreatic Neoplasms
• Sarcoma
• Soft Tissue Sarcoma
• Squamous Cell Carcinoma of Head and Neck
• Stomach Neoplasms

Intervention

Drug:
• SGN-CD47M
SGN-CD47M administered intravenously

Locations

Country	Name	City	State
United States	Case Western Reserve University / University Hospitals Cleveland Medical Center	Cleveland	Ohio
United States	MD Anderson Cancer Center / University of Texas	Houston	Texas
United States	Tennessee Oncology-Nashvilee/Sarah Cannon Research Institute	Nashville	Tennessee
United States	Providence Portland Medical Center	Portland	Oregon
United States	NEXT Oncology	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Seattle Genetics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with adverse events		Up to approximately 24 months
Primary	Number of patients with laboratory abnormalities		Up to approximately 24 months
Primary	Number of patients with dose-limiting toxicities (DLTs)		28 days
Secondary	Objective response rate (ORR) per RECIST v1.1	Defined as the proportion of patients with CR or PR	Up to approximately 2.5 years
Secondary	ORR per iRECIST	Defined as the proportion of patients with iCR or iPR	Up to approximately 2.5 years
Secondary	Duration of objective response (DOR) per RECIST v1.1	Defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever comes first	Up to approximately 2.5 years
Secondary	DOR per iRECIST		Up to approximately 2.5 years
Secondary	Duration of complete response (CR) per RECIST v1.1	Defined as the time from start of the first documentation of objective tumor response to the first documentation of confirmed tumor progression or to death due to any cause, whichever comes first for the subgroup of patients achieving a CR	Up to approximately 2.5 years
Secondary	Duration of CR per iRECIST		Up to approximately 2.5 years
Secondary	Progression-free survival (PFS) per RECIST v1.1	Defined as the time from start of study treatment to first documentation of disease progression or to death due to any cause, whichever comes first	Up to approximately 2.5 years
Secondary	PFS per iRECIST		Up to approximately 2.5 years
Secondary	Overall survival (OS)	Defined as the time from the start of any study treatment to the date of death due to any cause	Up to approximately 4 years
Secondary	Area under the concentration-time curve (AUC)		Up to approximately 24 months
Secondary	Maximum concentration (Cmax)		Up to approximately 24 months
Secondary	Time to Cmax (Tmax)		Up to approximately 24 months
Secondary	Trough concentration (Ctrough)		Up to approximately 24 months
Secondary	Incidence of antidrug antibodies (ADA)		Up to approximately 24 months